StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd.

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302252% above fair value
$361.27−9.06 (-2.45%)

Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –

BeOne Medicines External R&D by Year

External R&D — PARTRUVIX (pamiparib, PARP Inhibitor) ($M, FY17–FY23) ($M)

BeOne Medicines External R&D: $8.96M in FY2023, down 22.8% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2023
8.96
Period ended Dec 31, 2023
Change on a year earlier
-22.8%
11.6 in FY2022
History
7 years
Since FY2017
Sources
5
Documents cited below

Where the FY2023 figure comes from

“|| Pamiparib | 8,963 | 11,606”

Reported in Form 8-K EX-99.1 SSE STAR Market Annual Reports (688235.SS).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedExternal R&D — PARTRUVIX (pamiparib, PARP Inhibitor) ($M, FY17–FY23) ($M)Year on yearSource
FY2023Dec 31, 20238.96-22.8%8-K STAR Report (2024-04-26, 0001651308-24-000043) ↗
FY2022Dec 31, 202211.6-19.5%8-K STAR Report (2024-04-26, 0001651308-24-000043) ↗
FY2021Dec 31, 202114.4-48.8%8-K STAR Report (2023-04-25, 0001651308-23-000061) ↗
FY2020Dec 31, 202028.2-32.9%8-K STAR Report (2022-04-28, 0001651308-22-000058) ↗
FY2019Dec 31, 201941.9+9.4%8-K STAR Report (2021-11-16, 0001651308-21-000229) ↗
FY2018Dec 31, 201838.3+111.3%8-K STAR Report (2021-11-16, 0001651308-21-000229) ↗
FY2017Dec 31, 201718.1–8-K STAR Report (2021-01-29, 0001104659-21-009496) ↗

Cite this data

StockData. (2026). BeOne Medicines External R&D ($M), annual FY2017–FY2023 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-mol-pamiparib

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.